IL268626B2 - Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject - Google Patents

Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject

Info

Publication number
IL268626B2
IL268626B2 IL268626A IL26862619A IL268626B2 IL 268626 B2 IL268626 B2 IL 268626B2 IL 268626 A IL268626 A IL 268626A IL 26862619 A IL26862619 A IL 26862619A IL 268626 B2 IL268626 B2 IL 268626B2
Authority
IL
Israel
Prior art keywords
inactivated
lysate
equal parts
salmonella
beta
Prior art date
Application number
IL268626A
Other languages
Hebrew (he)
Other versions
IL268626A (en
IL268626B1 (en
Inventor
Alexandre Eduardo Nowill
Original Assignee
Alexandre Eduardo Nowill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/431,329 external-priority patent/US10213504B2/en
Application filed by Alexandre Eduardo Nowill filed Critical Alexandre Eduardo Nowill
Publication of IL268626A publication Critical patent/IL268626A/en
Publication of IL268626B1 publication Critical patent/IL268626B1/en
Publication of IL268626B2 publication Critical patent/IL268626B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (7)

1./ 1 CLAIMS 1. A synergistic pharmaceutical product comprising one or more antibiotics and: (a) i. 0,0036 ng/mL Koch’s Turberculin (inactivated Mycobacterium bovis lysate); ii. 0,0036 µg/mL PPD; iii. 6.31 µg/mL Inactivated Staphylococcus lysate (Staphylococcus aureus and Staphylococcus epidermidis in equal parts); iv. 6.31 µg/ml Inactivated Steptococcus lysate (Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus faecalis in equal parts); v. 0.404 µg/mL Streptokinase derived from inactivated beta-hemolytic Streptococcus lysate purification; vi. 0.101 µg/mL Dornase derived from inactivated beta-hemolytic Streptococcus lysate purification; vii. 6.31 µg/mL Oidiomycin (antigenic extract of Candida albicans); viii. 6.31 µg/mL Trichophytin (antigenic extract of Tricophyton sp); ix. 6.31 µg/mL Inactivated enteropathogenic Escherichia coli lysate (EPEC); x. 6.31 µg/mL Inactivated Salmonella lysate (Salmonella bongori, Salmonella enterica and Salmonella subterranea in equal parts); xi. 20 µg/mL Attenuated yellow fever virus strain 17 D204; xii. 7.5 mg/mL Sodium Chloride; xiii. 0.48 mg/mL Sodium phosphate dibasic heptahydrate; xiv. 0.06 mg/mL Potassium phosphate monobasic; xv. 2.5 mg/mL Phenol; and xvi. water; or (b) i. 0.004 ng/mL Koch’s Turberculin (inactivated Mycobacterium bovis lysate); ii. 0.004 g/mL PPD; iii. 6.94 µg/mL Inactivated Staphylococcus lysate (Staphylococcus aureus and Staphylococcus epidermidis in equal parts); iv. 6.94 µg/ml Inactivated Steptococcus lysate (Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus faecalis in equal parts); 268626/ 1 v. 0.444 µg/mL Streptokinase derived from inactivated beta-hemolytic Streptococcus lysate purification; vi. 0.111 µg/mL Dornase derived from inactivated beta-hemolytic Streptococcus lysate purification; vii. 6.94 µg/mL Inactivated Candida lysate (Candida albicans and Candida glabrata in equal parts); viii. 6.94 µg/mL Inactivated dermatophytes lysate (Epidermophytonfloccosum, Microsporum cannis, Trichophyton mentagrophytes of the interdigitale variety in equal parts); ix. 6.94 µg/mL Inactivated enteropathogenic Escherichia coli lysate (EPEC); x. 6.94 µg/mL Inactivated Salmonella lysate (Salmonella bongori, Salmonella enterica and Salmonella subterranea in equal parts); xi. 7.5 mg/mL Sodium Chloride; xii. 0.48 mg/mL Sodium phosphate dibasic heptahydrate; xiii. 0.06 mg/mL Potassium phosphate monobasic; xiv. 2.5 mg/mL Phenol; and xv. water.
2. The synergistic pharmaceutical product of claim 1 wherein the antibiotics are selected from the following classes: Amino Acid Derivatives, Aminoglycosides, Aureolic Acids, Aziridines, Ansamycins, Benzenoids, Benzimidazoles, Carbapenems, Cephalosporin, Coumarin-glycosides, Diphenyl Ether Derivatives, Epipolythiodioxopiperazines, Fatty Acid Derivatives, Glucosamine, Glycopeptides, Imidazoles, Indol Derivatives, Lipopeptides Macrolactams, Macrolides, Nucleosides. Penicillins and Cephalosporins (beta-Lactams), Peptides, Peptidyl Nucleosides, Phenicoles, Polyenes, Polyethers, Pyridines and Pyrimidines, Quinolones and Fluoroquinolones, Statins, Steroids, Sulfonamides, Taxoides and Tetracyclines.
3. The synergistic pharmaceutical product of claim 2 wherein the antibiotics are selected from the following classes: ansamycins, Penicillins, Cephalosporins, Carbapenems and Lipopeptides.
4. A synergistic effective amount of one or more antibiotics and (a) 268626/ 1 i. 0,0036 ng/mL Koch’s Turberculin (inactivated Mycobacterium bovis lysate); ii. 0,0036 µg/mL PPD; iii. 6.31 µg/mL Inactivated Staphylococcus lysate (Staphylococcus aureus and Staphylococcus epidermidis in equal parts); iv. 6.31 µg/ml Inactivated Steptococcus lysate (Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus faecalis in equal parts); v. 0.404 µg/mL Streptokinase derived from inactivated beta-hemolytic Streptococcus lysate purification; vi. 0.101 µg/mL Dornase derived from inactivated beta-hemolytic Streptococcus lysate purification; vii. 6.31 µg/mL Oidiomycin (antigenic extract of Candida albicans); viii. 6.31 µg/mL Trichophytin (antigenic extract of Tricophyton sp); ix. 6.31 µg/mL Inactivated enteropathogenic Escherichia coli lysate (EPEC); x. 6.31 µg/mL Inactivated Salmonella lysate (Salmonella bongori, Salmonella enterica and Salmonella subterranea in equal parts); xi. 20 µg/mL Attenuated yellow fever virus strain 17 D204; xii. 7.5 mg/mL Sodium Chloride; xiii. 0.48 mg/mL Sodium phosphate dibasic heptahydrate; xiv. 0.06 mg/mL Potassium phosphate monobasic; xv. 2.5 mg/mL Phenol; and xvi. water; or (b) i. 0.004 ng/mL Koch’s Turberculin (inactivated Mycobacterium bovis lysate); ii. 0.004 g/mL PPD; iii. 6.94 µg/mL Inactivated Staphylococcus lysate (Staphylococcus aureus and Staphylococcus epidermidis in equal parts); iv. 6.94 µg/ml Inactivated Steptococcus lysate (Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus faecalis in equal parts); v. 0.444 µg/mL Streptokinase derived from inactivated beta-hemolytic Streptococcus lysate purification; vi. 0.111 µg/mL Dornase derived from inactivated beta-hemolytic Streptococcus lysate purification; 268626/ 1 vii. 6.94 µg/mL Inactivated Candida lysate (Candida albicans and Candida glabrata in equal parts); viii. 6.94 µg/mL Inactivated dermatophytes lysate (Epidermophytonfloccosum, Microsporum cannis, Trichophyton mentagrophytes of the interdigitale variety in equal parts); ix. 6.94 µg/mL Inactivated enteropathogenic Escherichia coli lysate (EPEC); x. 6.94 µg/mL Inactivated Salmonella lysate (Salmonella bongori, Salmonella enterica and Salmonella subterranea in equal parts); xi. 7.5 mg/mL Sodium Chloride; xii. 0.48 mg/mL Sodium phosphate dibasic heptahydrate; xiii. 0.06 mg/mL Potassium phosphate monobasic; xiv. 2.5 mg/mL Phenol; and xv. water, for use in a method to treat sepsis and multi resistant bacterial infection in a human or an animal.
5. A synergistic effective amount of a composition comprising (a) i. 0,0036 ng/mL Koch’s Turberculin (inactivated Mycobacterium bovis lysate); ii. 0,0036 µg/mL PPD; iii.
6.31 µg/mL Inactivated Staphylococcus lysate (Staphylococcus aureus and Staphylococcus epidermidis in equal parts); iv. 6.31 µg/ml Inactivated Steptococcus lysate (Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus faecalis in equal parts); v. 0.404 µg/mL Streptokinase derived from inactivated beta-hemolytic Streptococcus lysate purification; vi. 0.101 µg/mL Dornase derived from inactivated beta-hemolytic Streptococcus lysate purification; vii. 6.31 µg/mL Oidiomycin (antigenic extract of Candida albicans); viii. 6.31 µg/mL Trichophytin (antigenic extract of Tricophyton sp); ix. 6.31 µg/mL Inactivated enteropathogenic Escherichia coli lysate (EPEC); x. 6.31 µg/mL Inactivated Salmonella lysate (Salmonella bongori, Salmonella enterica and Salmonella subterranea in equal parts); xi. 20 µg/mL Attenuated yellow fever virus strain 17 D204; 268626/ 1 xii.
7.5 mg/mL Sodium Chloride; xiii. 0.48 mg/mL Sodium phosphate dibasic heptahydrate; xiv. 0.06 mg/mL Potassium phosphate monobasic; xv. 2.5 mg/mL Phenol; and xvi. water; or (b) i. 0.004 ng/mL Koch’s Turberculin (inactivated Mycobacterium bovis lysate); ii. 0.004 g/mL PPD; iii. 6.94 µg/mL Inactivated Staphylococcus lysate (Staphylococcus aureus and Staphylococcus epidermidis in equal parts); iv. 6.94 µg/ml Inactivated Steptococcus lysate (Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus faecalis in equal parts); v. 0.444 µg/mL Streptokinase derived from inactivated beta-hemolytic Streptococcus lysate purification; vi. 0.111 µg/mL Dornase derived from inactivated beta-hemolytic Streptococcus lysate purification; vii. 6.94 µg/mL Inactivated Candida lysate (Candida albicans and Candida glabrata in equal parts); viii. 6.94 µg/mL Inactivated dermatophytes lysate (Epidermophytonfloccosum, Microsporum cannis, Trichophyton mentagrophytes of the interdigitale variety in equal parts); ix. 6.94 µg/mL Inactivated enteropathogenic Escherichia coli lysate (EPEC); x. 6.94 µg/mL Inactivated Salmonella lysate (Salmonella bongori, Salmonella enterica and Salmonella subterranea in equal parts); xi. 7.5 mg/mL Sodium Chloride; xii. 0.48 mg/mL Sodium phosphate dibasic heptahydrate; xiii. 0.06 mg/mL Potassium phosphate monobasic; xiv. 2.5 mg/mL Phenol; and xv. water, for use in a method to modulate an immune system response in a human or an animal who has a bacterial infection. For the Applicant Paulina Ben-Ami Patent Attorneys
IL268626A 2017-02-13 2018-02-15 Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject IL268626B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/431,329 US10213504B2 (en) 2011-03-18 2017-02-13 Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
PCT/BR2018/000004 WO2018145180A1 (en) 2017-02-13 2018-02-15 Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject

Publications (3)

Publication Number Publication Date
IL268626A IL268626A (en) 2019-10-31
IL268626B1 IL268626B1 (en) 2023-12-01
IL268626B2 true IL268626B2 (en) 2024-04-01

Family

ID=63106848

Family Applications (1)

Application Number Title Priority Date Filing Date
IL268626A IL268626B2 (en) 2017-02-13 2018-02-15 Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject

Country Status (10)

Country Link
EP (1) EP3579868A4 (en)
JP (1) JP2020507629A (en)
KR (1) KR20190139209A (en)
CN (1) CN110709099B (en)
AU (1) AU2018217441A1 (en)
BR (1) BR112019016670A2 (en)
IL (1) IL268626B2 (en)
MX (1) MX2019009689A (en)
RU (1) RU2019128674A (en)
WO (1) WO2018145180A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122618A1 (en) * 2011-03-17 2012-09-20 Nowill Alexandre Eduardo Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096270A1 (en) * 2003-04-30 2004-11-11 Medi Service S.R.L. Immunomodulating composition comprising a particulate fraction of bacterial mechanical lysates
CA2555253A1 (en) * 2004-02-06 2005-08-25 Yale University Compositions of pamps and listeria monocytogenes and methods of use
US20100166788A1 (en) * 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
EP1938835A1 (en) * 2006-12-29 2008-07-02 Pevion Biotech AG Non-specific immunostimulating agents
EP2303236A4 (en) * 2008-07-01 2012-09-26 Univ Emory Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors
CA2767536A1 (en) * 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
EP2464658B1 (en) * 2009-07-16 2014-10-01 Novartis AG Detoxified escherichia coli immunogens
US8980279B2 (en) * 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122618A1 (en) * 2011-03-17 2012-09-20 Nowill Alexandre Eduardo Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response

Also Published As

Publication number Publication date
EP3579868A4 (en) 2021-01-06
KR20190139209A (en) 2019-12-17
EP3579868A1 (en) 2019-12-18
IL268626A (en) 2019-10-31
RU2019128674A3 (en) 2021-06-18
BR112019016670A2 (en) 2020-04-14
JP2020507629A (en) 2020-03-12
AU2018217441A1 (en) 2019-10-03
CN110709099A (en) 2020-01-17
IL268626B1 (en) 2023-12-01
WO2018145180A1 (en) 2018-08-16
CN110709099B (en) 2024-03-29
RU2019128674A (en) 2021-03-16
MX2019009689A (en) 2019-12-18

Similar Documents

Publication Publication Date Title
Gomes et al. Control of bovine mastitis: old and recent therapeutic approaches
US9529005B2 (en) Modulating bacterial MAM polypeptides in pathogenic disease
López et al. Salmonella Typhimurium general virulence factors: A battle of David against Goliath?
MX2020004420A (en) Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same.
JP2013524844A5 (en)
Mosquito et al. Effect of bovine lactoferrin in Salmonella ser. Typhimurium infection in mice
EP2822582B1 (en) Multivalent vaccine protection from staphylococcus aureus infection
BR112019007928A2 (en) bacitracin-alginate oligomer conjugates
WO2020039359A3 (en) Escherichia coli compositions and methods thereof
IL268626B1 (en) Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
WO2023004415A3 (en) Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments
Huy et al. Intracellular trafficking modulation by ginsenoside Rg3 inhibits Brucella abortus uptake and intracellular survival within RAW 264.7 cells
Yatoo et al. Emerging antibiotic resistance in Mycoplasma microorganisms, designing effective and novel drugs/therapeutic targets: Current knowledge and futuristic prospects.
US20190083581A1 (en) Antibacterial composition containing adk protein as active ingredient, or composition for preventing or treating sepsis
MX2017007969A (en) Lactic acid bacteria and their use for the treatment of mastitis.
Daubenspeck et al. Identification of exopolysaccharide‐deficient mutants of Mycoplasma pulmonis
Lawrence et al. Map-based comparative genomic analysis of virulent Haemophilus parasuis serovars 4 and 5
EP1774975A1 (en) Use of human lysozyme in preparation of medicine for treating acne
Tonnaer et al. Advances in understanding the pathogenesis of pneumococcal otitis media
Gulbe et al. In vitro assessment for antimicrobial activity of Lactobacillus helveticus and its natural glycopeptides against mastitis causing pathogens in dairy cattle
WO2018035046A1 (en) Treating infections using idsd from proteus mirabilis
WO2017079161A3 (en) Treatment of neurodegenerative disease with sodium chlorite
Superti et al. Inv-mediated apoptosis of epithelial cells infected with enteropathogenic Yersinia: a protective effect of lactoferrin
Imran et al. A Comparative Study of Antimicrobial Profile Having Broad Spectrum Bacteriocins Against Antibiotics
Likaa et al. Immunostimulatory, Antibacterial and antibiofilm activity of purified Donkey colostrums lactoferrin on multidrug resistance Serratia liquefaciens producing Intl gene